On November 12, 2018 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will present at the Jefferies 2018 London Healthcare Conference in London, UK, taking place November 14 to 15, 2018 (Press release, AC Immune, NOV 12, 2018, View Source;jsessionid=I3EHPF-DGpWZMr3XX77giholoUVnI9bmt9_kIt_mqlDRUYKezPeM!702079892 [SID1234531208]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 London Healthcare Conference
Date: November 15, 2018 | 12:40 pm GMT
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune

A webcast of the presentation will be available on the Investor Page of AC Immune’s investor page and at the Jefferies 2018 Healthcare Conference website and will be active for 90 days following the event.